506128 Stock Overview
Manufactures and sells pharmaceutical formulations in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Parnax Lab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹119.10 |
| 52 Week High | ₹167.90 |
| 52 Week Low | ₹75.60 |
| Beta | 0.79 |
| 11 Month Change | -6.59% |
| 3 Month Change | 20.06% |
| 1 Year Change | 25.78% |
| 33 Year Change | 350.28% |
| 5 Year Change | 430.51% |
| Change since IPO | 1,317.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 506128 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.2% | -1.3% | -3.6% |
| 1Y | 25.8% | 59.4% | 40.0% |
Return vs Industry: 506128 underperformed the Indian Pharmaceuticals industry which returned 59.4% over the past year.
Return vs Market: 506128 underperformed the Indian Market which returned 40% over the past year.
Price Volatility
| 506128 volatility | |
|---|---|
| 506128 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: 506128 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 506128's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 12 | Mihir Shah | www.naxparlab.com |
Parnax Lab Limited manufactures and sells pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; and medicinal products. It provides cosmetic products; herbal; and nutraceutical products.
Parnax Lab Limited Fundamentals Summary
| 506128 fundamental statistics | |
|---|---|
| Market cap | ₹1.37b |
| Earnings (TTM) | ₹102.68m |
| Revenue (TTM) | ₹1.90b |
13.3x
P/E Ratio0.7x
P/S RatioIs 506128 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 506128 income statement (TTM) | |
|---|---|
| Revenue | ₹1.90b |
| Cost of Revenue | ₹987.80m |
| Gross Profit | ₹913.10m |
| Other Expenses | ₹810.42m |
| Earnings | ₹102.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.94 |
| Gross Margin | 48.04% |
| Net Profit Margin | 5.40% |
| Debt/Equity Ratio | 112.5% |
How did 506128 perform over the long term?
See historical performance and comparison